InhaleRX (ASX:IRX) Gains Phase 2 Approval for Non-Opioid Cancer Pain Therapy

3 min read | November 15, 2024 02:54 PM AEDT | By Team Kalkine Media

Google News:

InhaleRX (ASX:IRX) Gains Phase 2 Approval for Non-Opioid Cancer Pain Therapy — Image source: shutterstock

Recent News

Is ORG (ASX:ORG) Amid ASX 200 Signals a New Energy Divide?

What’s Driving AGL ASX 200 Into the Energy Spotlight?

Rio Tinto (ASX:RIO) Dividend Stocks Face a New Reality

Why BHP (ASX:BHP) ASX 200 Is Back in the Dividend Spotlight

Make Kalkine Media
My Trusted Source

Highlights

InhaleRX receives approval for Phase 2 trial to explore non-opioid cancer pain therapy.

IRX-211 aims to offer a safe, fast-acting pain relief alternative for cancer patients.

Non-opioid breakthrough could address a significant market demand for safer cancer pain treatments.

InhaleRX (ASX:IRX), a company specializing in inhaled drug-device therapies for pain and mental health management, has received regulatory approval to initiate a Phase 2 clinical trial for its innovative pain therapy, IRX-211. This non-opioid treatment is designed to address Breakthrough Cancer Pain (BTcP), a severe pain condition affecting many cancer patients, with a focus on offering a safer alternative to traditional opioid-based treatments.

This trial approval, granted by the Human Research Ethics Committee (HREC) of Belberry Ltd, is an essential step in advancing IRX-211. The therapy aims to provide rapid and effective relief without the risks associated with opioids, particularly fentanyl, which is commonly used in current treatments. The significance of this advancement is amplified by the estimated market potential, with the total addressable market for BTcP therapies valued at over US$1 billion, underscoring the demand for safer options.

According to InhaleRX CEO Darryl Davies, this approval marks a critical milestone for the company’s mission to deliver effective and safer pain management solutions for cancer patients. He emphasized the potential of IRX-211 to revolutionize pain management in cancer care, providing patients with a reliable, fast-acting therapeutic option that avoids the severe side effects and dependency risks associated with opioid medications.

In his statement, Davies expressed the company’s dedication to bringing this solution to patients who need rapid relief from BTcP. He highlighted the company’s commitment to addressing an unmet need within the healthcare market, where safe, effective non-opioid therapies for breakthrough pain are limited. He further acknowledged the dedication of the InhaleRX team in achieving this milestone, reflecting the company’s broader vision of transforming pain management in cancer care.

The market responded positively to this development, with InhaleRX’s share price rising on the announcement. At 11:06 AEDT, shares were trading at 3.5 cents, reflecting a 16.67% increase. This uptick indicates investor interest in the company’s progress and confidence in its innovative approach to tackling BTcP, which could have significant implications for both cancer treatment protocols and market dynamics in pain management.

As InhaleRX progresses with the Phase 2 trial, the company remains focused on meeting the pressing need for safer pain relief solutions, with IRX-211 positioned to make a meaningful impact in the lives of cancer patients seeking non-opioid alternatives.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.